{"id":"NCT02367794","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]","officialTitle":"A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-11","primaryCompletion":"2018-10-03","completion":"2021-02-17","firstPosted":"2015-02-20","resultsPosted":"2019-11-12","lastUpdate":"2022-03-21"},"enrollment":1021,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Squamous Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody","otherNames":["Tecentriq"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Nab-Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","type":"EXPERIMENTAL"},{"label":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","type":"EXPERIMENTAL"},{"label":"Arm C: Nab-Paclitaxel + Carboplatin","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.","primaryOutcome":{"measure":"Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population","timeFrame":"Up to approximately 30 months after first participant enrolled","effectByArm":[{"arm":"Arm C: Nab-Paclitaxel + Carboplatin","deltaMin":5.6,"sd":null},{"arm":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","deltaMin":6.5,"sd":null},{"arm":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":242,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","France","Germany","Israel","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Peru","Portugal","Russia","Singapore","Slovakia","Spain","Taiwan","Ukraine"]},"refs":{"pmids":["35511917"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":96,"n":334},"commonTop":["ANAEMIA","ALOPECIA","NAUSEA","FATIGUE","NEUTROPENIA"]}}